Journal of Drug Targeting最新文献_第10页

Mitochondria-targeted nanocarriers for smart response delivery of natural products: a review. 天然产物智能响应递送的线粒体靶向纳米载体：综述。

IF 4.7 4区医学

Journal of Drug Targeting Pub Date : 2026-08-01 Epub Date: 2026-01-12 DOI: 10.1080/1061186X.2025.2611940

Jiansheng Cao, Wenfei Lu, Ying Lv, Meng Li, Ye Tang, Yufei Feng

{"title":"Mitochondria-targeted nanocarriers for smart response delivery of natural products: a review.","authors":"Jiansheng Cao, Wenfei Lu, Ying Lv, Meng Li, Ye Tang, Yufei Feng","doi":"10.1080/1061186X.2025.2611940","DOIUrl":"10.1080/1061186X.2025.2611940","url":null,"abstract":"Mitochondrial dysfunction is closely associated with the onset and progression of various major diseases, including cancer and neurodegenerative disorders. The design of smart nanomaterial-natural product composite systems offers an innovative strategy for multifunctional nanocarriers. These smart carriers not only enable precise, controlled release of active components at specific mitochondrial targets but also provide novel technical support for natural products to overcome various barriers encountered during in vivo administration, thereby enhancing bioavailability. This review systematically summarises the latest research advances in mitochondria-targeted nano-drug delivery systems based on smart responsive principles for delivering natural products. It focuses on exploring the design principles, mechanisms of action, and representative applications of various responsive systems (including pH-, enzyme-, redox-, temperature-, light-, magnetic-, and ultrasound-responsive systems). Furthermore, existing challenges and unexplored therapeutic opportunities through interdisciplinary strategies integrating AI technology, CRISPR gene editing, and biomimetic materials are also highlighted and discussed to inspire the next generation of mitochondrial-targeted nanotherapeutics.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1116-1132"},"PeriodicalIF":4.7,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145933393","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

SKQ1: a mitochondria-targeted antioxidant with therapeutic potential. SKQ1：一种具有治疗潜力的线粒体靶向抗氧化剂。

IF 4.7 4区医学

Journal of Drug Targeting Pub Date : 2026-08-01 Epub Date: 2026-01-14 DOI: 10.1080/1061186X.2026.2613054

Ruolan Wu, Yuan Wu

引用次数: 0

Nanovesicles-enabled concurrent delivery of cyclosporine and Vitamin D for topical treatment of psoriasis. 纳米囊泡使环孢素和维生素D同时递送用于局部治疗银屑病。

IF 4.7 4区医学

Journal of Drug Targeting Pub Date : 2026-08-01 Epub Date: 2025-12-22 DOI: 10.1080/1061186X.2025.2604148

Kailas Moravkar, Vishakha Ipar, Kalpesh R Patil, Shailesh Chalikwar, Pradip Nirbhavane

{"title":"Nanovesicles-enabled concurrent delivery of cyclosporine and Vitamin D for topical treatment of psoriasis.","authors":"Kailas Moravkar, Vishakha Ipar, Kalpesh R Patil, Shailesh Chalikwar, Pradip Nirbhavane","doi":"10.1080/1061186X.2025.2604148","DOIUrl":"10.1080/1061186X.2025.2604148","url":null,"abstract":"Psoriasis is a chronic autoimmune skin disease, which affects the quality of life of patients. Cyclosporine (Cys-A) & Vitamin D (Vit D3) are crucial drugs used in the treatment of the disease. They are mainly administered via oral dosage forms for the treatment of psoriasis. However, their conventional dosage forms suffer from low oral bioavailability, along with systemic adverse effects. Developing the topical dosage forms of these drugs can be advantageous to overcome the problems associated with conventional therapy. Hence, ethosomes (ETH) were developed for the simultaneous administration of both the drugs. The particle size of the developed ethosomes was found to be 120.8 ± 5.6 nm, zeta potential value was found to be -24.7 ± 1.5 and entrapment efficiency was found to be 74.8 ± 1.52% & 80 ± 1.8% respectively, for Cys-A and Vit D3. In vitro drug release studies exhibited drug release of about 74% and 78% for Cys-A & Vit D3, respectively. Skin permeation studies demonstrated significantly higher drug permeation of ETH gel for Cys-A & Vit-D3 (71.6% and 72.2% respectively) than the conventional gel formulation (52.9% and 54.8% respectively). A cytotoxicity study conducted on the HaCaT cell line showed no cytotoxicity with ≥ 90% of cell viability. The therapeutic efficacy of the formulation tested on the in-vivo antipsoriatic rat model demonstrated comparable efficacy to that of the marketed formulation and the signs of inflammation were reverted within 14 days.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1234-1245"},"PeriodicalIF":4.7,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145756777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nanomedicines: an update of diagnostic and therapeutic applications in multiple cancers. 纳米药物：多种癌症诊断和治疗应用的最新进展。

IF 4.7 4区医学

Journal of Drug Targeting Pub Date : 2026-08-01 Epub Date: 2026-01-13 DOI: 10.1080/1061186X.2026.2613059

Sani Jaysing Shinde, Priyanka, Manju Jakhar, Isha Arora, Deepika Sehgal, Mahak, Anupama Kumari, Tamanna Dhiman, Priya, Narender Kumar, Vishal Kumar, Sunny Kumar

{"title":"Nanomedicines: an update of diagnostic and therapeutic applications in multiple cancers.","authors":"Sani Jaysing Shinde, Priyanka, Manju Jakhar, Isha Arora, Deepika Sehgal, Mahak, Anupama Kumari, Tamanna Dhiman, Priya, Narender Kumar, Vishal Kumar, Sunny Kumar","doi":"10.1080/1061186X.2026.2613059","DOIUrl":"10.1080/1061186X.2026.2613059","url":null,"abstract":"Cancer remains a major global health challenge, with existing diagnostic and therapeutic strategies often limited by poor selectivity, systemic toxicity and resistance. Nanomedicine - a convergence of nanotechnology and molecular medicine - offers promising solutions to these limitations by enabling more precise cancer diagnosis and effective treatment. Engineered nanoparticles (NPs) such as liposomes, polymeric micelles, dendrimers and metallic NPs have been widely studied for their ability to deliver therapeutic agents or genetic materials directly to tumours. NPs can exploit the enhanced permeability and retention (EPR) effect for passive targeting and can be further functionalised with ligands for active targeting of tumour-specific markers such as EGFR, HER2 or folate receptors. In diagnostics, nanoprobes and nanobiosensors enable high-resolution imaging modalities including MRI, PET and optical imaging, allowing early tumour detection and real-time monitoring. Moreover, multifunctional theranostic NPs integrate both therapeutic and diagnostic functions in a single platform. Recent innovations also include nanocarriers for RNA interference, CRISPR-Cas9 delivery and stimuli-responsive drug release. Additionally, NPs are being explored for photothermal therapy (PTT) and radio-sensitisation to further enhance treatment outcomes. This review summarises recent progress in nanomedicine applications across multiple cancer types - lung, breast, brain, liver and gastrointestinal - and correlates these developments with tumour biology and microenvironmental factors.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1147-1180"},"PeriodicalIF":4.7,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145900586","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The role of MSC-derived exosomes in immune modulation and regenerative medicine. msc衍生外泌体在免疫调节和再生医学中的作用。

IF 4.7 4区医学

Journal of Drug Targeting Pub Date : 2026-08-01 Epub Date: 2026-01-28 DOI: 10.1080/1061186X.2026.2620707

Surya Nath Pandey, Muhammad Afzal, Kavita Goyal, Rekha M M, Priya Priyadarshini Nayak, Mudasir Maqbool, Yumna Khan, Chandana Maji, Gaurav Gupta, Sami I Alzarea, Imran Kazmi, Md Sadique Hussain

{"title":"The role of MSC-derived exosomes in immune modulation and regenerative medicine.","authors":"Surya Nath Pandey, Muhammad Afzal, Kavita Goyal, Rekha M M, Priya Priyadarshini Nayak, Mudasir Maqbool, Yumna Khan, Chandana Maji, Gaurav Gupta, Sami I Alzarea, Imran Kazmi, Md Sadique Hussain","doi":"10.1080/1061186X.2026.2620707","DOIUrl":"10.1080/1061186X.2026.2620707","url":null,"abstract":"Background: Mesenchymal stem cell (MSC)-derived exosomes have emerged as promising cell-free therapeutic agents in immunomodulation and regenerative medicine. These extracellular vesicles transport bioactive lipids, proteins, and nucleic acids that mediate intercellular communication.Methods: This narrative review summarizes current strategies for isolating MSC-derived exosomes, including ultracentrifugation, size-exclusion chromatography, and immunoaffinity capture, and evaluates their functional cargo and therapeutic applications.Results: MSC-derived exosomes exhibit potent immunomodulatory effects, including suppression of pro-inflammatory cytokines, expansion of regulatory T cells, and promotion of anti-inflammatory microenvironments. They demonstrate therapeutic potential across autoimmune, cardiovascular, oncologic, and neurodegenerative disease models. Engineered exosomes further show promise as targeted drug-delivery systems, particularly in oncology, by enhancing drug bioavailability and overcoming chemoresistance. Compared with MSC-based therapies, exosomes offer advantages such as reduced safety concerns and improved stability.Conclusion: By integrating cargo-specific immune modulation with organ-specific regenerative outcomes, MSC-derived exosomes represent a versatile therapeutic platform. Standardized purification methods and further clinical studies are essential to advance their translational and clinical applications.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1181-1199"},"PeriodicalIF":4.7,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146029768","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Venlafaxine suppressed PD-L1 expression through oxidative stress and improved anti-tumour immune responses in melanoma mice. 文拉法辛通过氧化应激抑制PD-L1表达，改善黑色素瘤小鼠的抗肿瘤免疫反应。

IF 4.7 4区医学

Journal of Drug Targeting Pub Date : 2026-08-01 Epub Date: 2026-01-20 DOI: 10.1080/1061186X.2025.2609200

Mingyu Mo, Lirui Liang, Kairun Li, Weiwei Ren, Yuqing Wei, Mengyu Lei, Aoyuan Fan, Panpan Guo, Sheng Guo, Yongxi Zhang, Huijie Jia, Tiesuo Zhao

{"title":"Venlafaxine suppressed PD-L1 expression through oxidative stress and improved anti-tumour immune responses in melanoma mice.","authors":"Mingyu Mo, Lirui Liang, Kairun Li, Weiwei Ren, Yuqing Wei, Mengyu Lei, Aoyuan Fan, Panpan Guo, Sheng Guo, Yongxi Zhang, Huijie Jia, Tiesuo Zhao","doi":"10.1080/1061186X.2025.2609200","DOIUrl":"10.1080/1061186X.2025.2609200","url":null,"abstract":"Melanoma is an aggressive cutaneous malignancy characterised by high metastatic potential and poor prognosis. Oxidative stress plays a pivotal role in melanoma pathogenesis, as tumour cells exploit reactive oxygen species (ROS) to promote survival, drive progression, and regulate critical signalling pathways-including the expression of programmed death-ligand 1 (PD-L1), a key immune checkpoint molecule that facilitates immune evasion. This study aimed to investigate whether venlafaxine, a compound with known biological activities, could modulate oxidative stress to suppress PD-L1 expression and enhance anti-tumour immune responses in melanoma. In vitro experiments demonstrated that venlafaxine significantly inhibited melanoma cell proliferation and migration, accompanied by a marked reduction in intracellular ROS production and altered expression of PD-L1-related proteins. In a murine melanoma model, venlafaxine administration effectively retarded tumour growth, downregulated PD-L1 levels in tumour tissues, promoted the infiltration of T lymphocytes into the tumour microenvironment, and increased the proportion of T lymphocytes in the spleen. Collectively, these findings indicate that venlafaxine exerts anti-melanoma effects by mitigating ROS release and potentiating anti-tumour immune responses, thereby highlighting its potential as a therapeutic candidate for melanoma treatment.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1291-1300"},"PeriodicalIF":4.7,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145810071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

ICAM-1 targeting of nanocarriers in a human blood-brain-barrier-on-a-chip complements in vivo brain delivery observations. ICAM-1靶向纳米载体在人血脑屏障芯片上的补充在体内脑递送观察。

IF 4.7 4区医学

Journal of Drug Targeting Pub Date : 2026-08-01 Epub Date: 2025-12-18 DOI: 10.1080/1061186X.2025.2600101

Marco Vigo, Sujey Palma-Florez, Rita Grimalt-Mirada, Marina Placci, Andrés Crespo, Marina I Giannotti, Anna Lagunas, Mònica Mir, Josep Samitier, Silvia Muro

{"title":"ICAM-1 targeting of nanocarriers in a human blood-brain-barrier-on-a-chip complements in vivo brain delivery observations.","authors":"Marco Vigo, Sujey Palma-Florez, Rita Grimalt-Mirada, Marina Placci, Andrés Crespo, Marina I Giannotti, Anna Lagunas, Mònica Mir, Josep Samitier, Silvia Muro","doi":"10.1080/1061186X.2025.2600101","DOIUrl":"10.1080/1061186X.2025.2600101","url":null,"abstract":"Targeting therapeutic nanocarriers (NCs) to endothelial receptors favours transport across the blood-brain barrier (BBB), a main obstacle to access the brain. While these strategies compel validation in animals, quantitative sub-cellular resolution is non-viable in vivo. BBB-on-chip (BBB-oC) devices can help. Illustrating this, we used a BBB-oC comprising a lateral channel containing a human brain endothelial lining and a central chamber containing hydrogel-embedded pericytes and astrocytes. We studied NCs targeting intercellular adhesion molecule-1 (ICAM-1), a cell-surface protein overexpressed in pathology and involved in CAM-mediated transport. Brain access was validated in vivo after injection of NCs coated with anti-ICAM-1 vs. control IgG. ICAM-1 expression was verified in vitro using endothelial cells, pericytes, and astrocytes (756-, 511-, 690-fold over non-specific signal under TNFα). VE-cadherin presence and lack of dextran leakage demonstrated a restrictive BBB-oC barrier. Data showed endothelial targeting of anti-ICAM-1 NCs (428 NCs/cell at 1 h), uptake (60% of cell-interacting NCs), and transcytosis (90%; 24 h) downregulated by a CAM-pathway inhibitor (88% decay; 1 h). Non-transcyosed NCs trafficked to lysosomes, while transcytosed NCs interacted with pericytes and astrocytes (2643 NCs/cell; 24 h) and entered them (90% of transcytosed NCs). This BBB-oC represents a valuable model to evaluate ICAM-1-mediated transcytosis, complementing animal studies.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1210-1223"},"PeriodicalIF":4.7,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13231930/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145701136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exploring chitosan/clay microparticles enriched with fenugreek extract as a potential treatment strategy for infectious diarrhea: preclinical investigation. 探索富含胡芦巴提取物的壳聚糖/粘土微颗粒作为感染性腹泻的潜在治疗策略：临床前研究。

IF 4.7 4区医学

Journal of Drug Targeting Pub Date : 2026-08-01 Epub Date: 2026-04-09 DOI: 10.1080/1061186X.2025.2596083

Yan Cheng

引用次数: 0

Design, optimization, and in vivo assessment of in situ pH-sensitive quercetin transbilosomes for the treatment of diabetes mellitus-associated heart failure. 原位ph敏感槲皮素跨胆囊体治疗糖尿病相关性心力衰竭的设计、优化和体内评价

IF 4.7 4区医学

Journal of Drug Targeting Pub Date : 2026-08-01 Epub Date: 2026-02-02 DOI: 10.1080/1061186X.2026.2621844

Wenxue Jin, Marwa H Elkarmalawy, Amr Gamal Fouad, Amany Belal, Alaa Ismail, Mohamed A M Ali, Nisreen Khalid Aref Albezrah, Samar F Miski, Fatma I Abo El-Ela, Marwa M Nagib

{"title":"Design, optimization, and in vivo assessment of in situ pH-sensitive quercetin transbilosomes for the treatment of diabetes mellitus-associated heart failure.","authors":"Wenxue Jin, Marwa H Elkarmalawy, Amr Gamal Fouad, Amany Belal, Alaa Ismail, Mohamed A M Ali, Nisreen Khalid Aref Albezrah, Samar F Miski, Fatma I Abo El-Ela, Marwa M Nagib","doi":"10.1080/1061186X.2026.2621844","DOIUrl":"10.1080/1061186X.2026.2621844","url":null,"abstract":"Quercetin (QCT) is an effective flavonoid that offers protection against diabetes mellitus-associated heart failure (HF) due to its antioxidant properties. The effectiveness of QCT is, however, constrained by its low bioavailability and poor solubility. An in-situ pH-sensitive formulation of QCT-loaded transbilosomes (IPSQLT) was developed for nasal administration. This formulation aims to enhance sustainability, bioavailability, permeability, and the effectiveness of QCT in treating diabetes-associated HF. To determine the optimal QLT formulation, various formulations were developed using the Box-Behnken design. The IPSQLT formulation was developed by incorporating an optimal QLT formulation along with chitosan and glyceryl monooleate. The in vivo study employed an experimental diabetes and HF-induced rat model to evaluate the bioavailability and effectiveness of the IPSQLT formulation. The IPSQLT formulation enhanced QCT's sustainability, permeability, and bioavailability by 60.64%, 7.11 times, and 7.37 times, respectively, compared to free QCT. The nasal IPSQLT formulation significantly reduced levels of glucose, LDH, CK-MB, troponin-1, and MDA compared to the positive control group, with reductions of 92.52%, 97.89%, 93.22%, 97.60%, and 98.79%, respectively. Additionally, IPSQLT elevated the levels of GSH, SOD, and CAT by 3.41-fold, 3.13-fold, and 3.13-fold, respectively. These findings suggest that nasal IPSQLT could serve as a potential treatment option for diabetes-associated heart failure.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1359-1375"},"PeriodicalIF":4.7,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146040871","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Triphenylphosphonium-functionalised cubosomes for mitochondrial-targeted delivery of 5-fluorouracil and lycopene in skin cancer therapy. 线粒体靶向递送5-氟尿嘧啶和番茄红素的三苯基膦功能化立方体体在皮肤癌治疗中的应用

IF 4.7 4区医学

Journal of Drug Targeting Pub Date : 2026-08-01 Epub Date: 2026-01-20 DOI: 10.1080/1061186X.2026.2614975

Mohd Shoab Ali, Tenzin Sonam Dongsar, Niladri Haldar, Virendra Gajbhiye, Mohd Aqil, Prashant Kesharwani

{"title":"Triphenylphosphonium-functionalised cubosomes for mitochondrial-targeted delivery of 5-fluorouracil and lycopene in skin cancer therapy.","authors":"Mohd Shoab Ali, Tenzin Sonam Dongsar, Niladri Haldar, Virendra Gajbhiye, Mohd Aqil, Prashant Kesharwani","doi":"10.1080/1061186X.2026.2614975","DOIUrl":"10.1080/1061186X.2026.2614975","url":null,"abstract":"The importance of mitochondria in cancer is undeniable, as they serve as a vital centre for energy metabolism and regulating apoptosis. Herein, we engineered cubosomes as a nanocarrier with encapsulation of the chemotherapeutic agent 5-fluorouracil and an antioxidant with reported antitumor activity, lycopene. The formulation was fabricated by utilising glyceryl monooleate, oleic acid, and polaxamer-407, facilitating simultaneous encapsulation of hydrophobic lycopene and hydrophilic 5-fluorouracil. To target mitochondria, the nanoparticle surface was decorated with triphenylphosphine, a lipophilic cation known to gather within the negatively charged mitochondrial membrane. Physicochemical evaluation verified nanoscale particle size (158.7 nm), uniform distribution (0.2482 PDI), and high encapsulation efficiency (79 ± 5.2% for 5-FU and 85 ± 7.1% for lycopene). The synergistic impact of 5-FU-induced DNA synthesis suppression and lycopene-mediated mitochondrial oxidative stress was augmented by TPP-driven mitochondrial accumulation, resulting in significant apoptotic activity in cancer cells, as confirmed in in vitro cytotoxicity assays and in vivo animal studies. These findings highlight the potential of synergism of 5-FU and lycopene in skin cancer and also the potential of TPP-functionalised entrapped dual-drug-loaded cubosomes in mitochondrial targeting of skin cancerous cells.","PeriodicalId":15573,"journal":{"name":"Journal of Drug Targeting","volume":" ","pages":"1334-1358"},"PeriodicalIF":4.7,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145959572","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0